Bacterial live vector vaccines expressing chromosomally-integrated foreign antigens
Bacterial live vector vaccines represent a vaccine development strategy that offers exceptional flexibility. In the present invention, genes encoding protective antigens of unrelated bacterial, viral, parasitic, or fungal pathogens are expressed in an attenuated bacterial vaccine strain that delivers these foreign antigens to the immune system, thereby eliciting relevant immune responses. Rather than expressing these antigens using only low copy expression plasmids, expression of foreign proteins is accomplished using both low copy expression plasmids in conjunction with chromosomal integrations within the same live vector. This strategy compensates for the inherent disadvantage of loss of gene dosage (versus exclusive plasmid-based expression) by integrating antigen expression cassettes into multiple chromosomal sites already inactivated in an attenuated vector.
1. An attenuated strain of Salmonella enterica serovar typhi ( S. typhi ) having disruptions of three or more chromosomal locations, said locations selected from the group consisting of the guaBA locus, the htrA locus, the clyA locus, the rpoS locus, and the ssb locus.
2. The attenuated strain of claim 1 , wherein the attenuated strain is the strain CVD 910 which has disruptions of the guaBA locus, the htrA locus, and the rpoS locus.
3. The attenuated strain of claim 1 , wherein the attenuated strain further comprises a chromosomal-based expression system integrated into each location of chromosomal disruption, and wherein each chromosomal-based expression system comprises an expression cassette encoding an antigen.
4. The attenuated strain of claim 3 , wherein each expression cassette individually encodes an antigen selected from the group consisting of the cell binding domain of C. difficile toxin A (CBD/A), the cell binding domain of C. difficile toxin B (CBD/B), and the cell binding domain of C. difficile binary toxin.
5. The attenuated strain of claim 3 , wherein the attenuated strain has disruptions of the guaBA locus, the htrA locus, and the rpoS locus.
6. The attenuated strain of claim 3 , wherein the attenuated strain is the strain CVD 910-3A which has disruptions of the guaBA locus, the htrA locus, and the rpoS locus, and wherein each expression cassette encodes the cell binding domain of C. difficile toxin A.
7. The attenuated strain of claim 3 , wherein the attenuated strain further comprises (one or more plasmid-based expression systems, and wherein each plasmid-based expression system encodes an antigen.
8. The attenuated strain of claim 7 , wherein each expression cassette individually encodes an antigen selected from the group consisting of the cell binding domain of C. difficile toxin A (CBD/A), the cell binding domain of C. difficile toxin B (CBD/B), and the cell binding domain of C. difficile binary toxin.
9. The attenuated strain of claim 7 , wherein one of the locations of chromosomal disruption is the ssb locus and the plasmid-based expression system is an SSB-stabilized plasmid-based expression system.
10. The attenuated strain of claim 7 , wherein the attenuated strain is the strain CVD 910-3Assb which has disruptions of the guaBA locus, the htrA locus, the rpoS locus and the ssb locus, wherein each expression cassette encodes the cell binding domain of C. difficile toxin A, and wherein the plasmid-based expression system is an SSB-stabilized plasmid-based expression system.
11. The attenuated strain of claim 7 , wherein the attenuated strain is the strain CVD 910-3Assb(pSEC10-CBD/B) which has disruptions of the guaBA locus, the htrA locus, the rpoS locus and the ssb locus, wherein each expression cassette encodes the cell binding domain of C. difficile toxin A, and wherein the plasmid-based expression system is an SSB-stabilized plasmid-based expression system encoding the cell binding domain of C. difficile toxin B.
12. The attenuated strain of claim 7 , wherein the attenuated strain comprises (disruptions of the guaBA locus, the htrA locus, the clyA locus, and the rpoS locus,
wherein the chromosomal-based expression system integrated into the guaBA chromosomal disruption comprises an expression cassette encoding the binary toxin (BT) of C. difficile,
wherein the chromosomal-based expression systems integrated into each of the htrA, clyA and rpoS chromosomal disruptions comprise expression cassettes encoding the cell binding domain of C. difficile toxin A (CBD/A), and
wherein the plasmid-based expression system encodes the cell binding domain of C. difficile toxin B (CBD/B).
13. The attenuated strain of claim 12 , wherein the attenuated strain further comprises a disruption of the ssb locus and the plasmid-based expression system is a SSB-stabilized plasmid-based expression system.
14. The attenuated strain of claim 13 , wherein the attenuated strain is CVD 910-3A-GB2ssb(pSEC10-CBD/B).
15. The attenuated strain of claim 12 formulated as a pharmaceutical composition comprising a pharmaceutically-acceptable carrier or diluent.
16. A method of inducing an immune response to an antigen in a subject, comprising administering to a subject the pharmaceutical composition according to claim 15 .